home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »


$80 million

Medical Device

Feb9Tandem Diabetes Care Announces Pricing of $60 Million Underwritten Public Offering of Common Stock »

Mar23Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock »

Nov29Tandem Diabetes Care to Draw Down $35 Million under Existing Term Loan Facility with CRG »

Jan12Tandem Diabetes Care Amends Term Loan Facility with CRG »

Sep9Tandem Diabetes Care Announces FDA Approval of t:slim G4 Insulin Pump with CGM Integration »

Jul30Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems »

May19Tandem Diabetes Care Launches t:flex™ Insulin Pump »

Mar4Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock »

Jan12Tandem Diabetes Care Announces FDA Clearance of the t:flex™ Insulin Pump »

Apr9Tandem Diabetes Care and Capital Royalty Amend and Restate Term Loan Facility »

Tandem Diabetes Care Prices Initial Public Offering »

SAN DIEGO, CA, November 13, 2013 - Tandem Diabetes Care®, Inc. ("Tandem"), a medical device company and manufacturer of the t:slim® Insulin Pump, today announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price of $15.00 per share. In addition, Tandem has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the initial public offering price. All of the shares are being offered by Tandem. The shares are expected to begin trading tomorrow, November 14, 2013, on the NASDAQ Global Market under the ticker symbol "TNDM." The offering is expected to close on November 19, 2013, pending customary closing conditions.


BofA Merrill Lynch and Piper Jaffray are acting as joint book-running managers for the offering. Deutsche Bank Securities and Stifel are acting as co-managers.


A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on November 13, 2013. When available, copies of the final prospectus may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038 Attention: Prospectus Department, by email at dg.Prospectus_Requests@baml.com; or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or by email at prospectus@pjc.com.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Tandem Diabetes Care, Inc.


Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in San Diego, California.

Jan23Tandem Diabetes Care and Capital Royalty Close Term Loan Facility »